
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb Inc. demonstrated positive financial momentum in its 1Q25 results, reporting revenues of $4.2 million, which reflects a 9% year-over-year increase, alongside reduced net losses of $18.2 million, improving from a loss of $19.0 million in the previous year. The company's solid balance sheet further strengthens its prospects, providing a firm foundation for sustained growth. Additionally, anticipated near- and long-term R&D catalysts are expected to drive continued upward momentum for the stock, aligning with the company's commitment to advancing its innovative therapeutic antibody discovery technologies.
Bears say
OmniAb Inc. experienced a decline in its stock value following its November 2022 merger with Avista Public Acquisition Corporation II, likely due to negative market conditions impacting both similar mergers and established biotechnology companies. The company's guidance on operating cash burn indicates a persistent concern about financial sustainability, as it expects lower cash burn in 2023 compared to the anticipated burn in 2024. These factors, combined with overall market dynamics, contribute to a negative outlook for OmniAb's stock performance.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares